+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Biologics Contract Manufacturing Market by Molecule Type, Process Step, Production Scale, Technology Platform, Therapeutic Area, End User, Manufacturing Model - Global Forecast to 2030- Product Image
Biologics Contract Manufacturing Market by Molecule Type, Process Step, Production Scale, Technology Platform, Therapeutic Area, End User, Manufacturing Model - Global Forecast to 2030- Product Image
Sale

Biologics Contract Manufacturing Market by Molecule Type, Process Step, Production Scale, Technology Platform, Therapeutic Area, End User, Manufacturing Model - Global Forecast to 2030

  • PDF Icon

    Report

  • 181 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6011401
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Biologics Contract Manufacturing Market grew from USD 26.53 billion in 2024 to USD 31.04 billion in 2025. It is expected to continue growing at a CAGR of 16.85%, reaching USD 67.56 billion by 2030.

Navigating the Expanding Biologics Contract Manufacturing Frontier

The biologics contract manufacturing sector is experiencing an unprecedented evolution driven by advances in therapeutic modalities and increasing outsourcing demands from pharmaceutical and biotechnology sponsors. As complex biologics such as cell therapies and gene therapies move from discovery into development and commercialization, the need for specialized manufacturing infrastructure and expertise has never been more acute. This introduction lays the groundwork for understanding the critical factors reshaping the industry and highlights the strategic considerations organizations must address to remain competitive. It underscores the convergence of scientific innovation, regulatory rigor, and commercial imperatives, establishing a foundation for the subsequent examination of market dynamics.

Emerging Forces Reshaping the Biologics Manufacturing Landscape

In recent years, several transformative shifts have redefined the biologics contract manufacturing landscape. Process intensification and continuous manufacturing platforms have begun to replace traditional batch processes, accelerating timelines and reducing footprint requirements. Meanwhile, the rise of personalized medicine has amplified demand for small-batch, flexible production capabilities tailored to niche indications, challenging established players to adapt rapidly.

Regulatory frameworks have also evolved, with agencies placing greater emphasis on quality by design and real-time process monitoring, fostering closer collaboration between sponsors and service providers. At the same time, digital tools-from advanced analytics to digital twins-are enabling enhanced process control, predictive maintenance, and data-driven decision-making across the manufacturing continuum.

Geographically, emerging hubs are gaining prominence as service providers expand capacity in regions offering cost efficiencies, skilled talent pools, and supportive government incentives. Sustainability considerations, including single-use technologies that minimize water and energy consumption, further underscore the industry’s commitment to environmental stewardship. Together, these forces are driving a new era of agility and responsiveness in biologics manufacturing.

Assessing the 2025 US Tariffs and Their Ripple Effects

The introduction of updated tariffs by the United States in 2025 has reverberated through global supply chains, prompting a thorough reassessment of sourcing strategies for raw materials, consumables, and equipment. Manufacturers that historically relied on cross-border imports for critical reagents and stainless steel components now face increased input costs and potential delivery delays. This environment has heightened the appeal of near-shoring initiatives and the establishment of regional production sites to mitigate exposure to tariff-induced price volatility.

Contract development and manufacturing organizations are responding by diversifying supplier networks, negotiating longer-term procurement agreements, and exploring alternative materials where feasible. Some have accelerated investments in onshore capabilities to shield their operations from future trade disruptions, while others are collaborating more closely with regulators to streamline import-export processes and secure tariff exemptions for clinical and critical therapy supplies.

Although increased operating expenses present a short-term challenge, these adjustments are catalyzing improvements in supply chain resilience and regional self-sufficiency, ultimately supporting more reliable and cost-effective biologics production.

Unveiling Critical Segmentation Dynamics in Biologics Manufacturing

Analysis of molecule type reveals a heterogeneous landscape where monoclonal antibodies continue to represent a stable volume segment, yet emergent modalities such as gene therapy and cell therapy are commanding disproportionate investment in manufacturing capacity, reflecting their high-value therapeutic potential. At the same time, recombinant proteins and vaccines maintain critical roles in addressing large-scale healthcare needs, balancing innovation with proven process scalability.

When examining process steps, upstream bioreactor development is attracting significant attention for its potential to optimize titers, while downstream purification remains essential for ensuring product purity and yield. Formulation and fill-finish capabilities are increasingly integrated into end-to-end service offerings, and analytical testing has grown in complexity as regulatory expectations around characterization and release testing intensify.

In terms of production scale, facilities dedicated to Phase III and commercial-scale batches are expanding rapidly to accommodate late-stage pipelines, whereas preclinical and early-phase operations prioritize flexibility and quick turnaround. Technology platforms demonstrate a clear shift toward single-use systems, prized for their rapid deployment and lower cleaning validation burden, although stainless steel remains indispensable for high-volume, long-term runs.

Therapeutic area segmentation highlights oncology as a dominant driver of capacity expansion, while rare disease and autoimmune indications, despite smaller patient populations, command specialized manufacturing processes. Infectious disease vaccine production sees cyclical surges aligned with epidemiological trends.

From an end user perspective, biotechnology companies increasingly seek partnerships with contract service providers that can seamlessly integrate technical expertise and regulatory support. Pharmaceutical companies leverage external manufacturing to optimize internal resources, and research institutes focus on early-stage production to advance proof-of-concept studies.

Manufacturing models are also diversifying: dedicated facilities offer high control for strategic products, fee-for-service arrangements allow flexibility, multiproduct facilities maximize asset utilization, and virtual manufacturing networks enable leaner capital deployment.

Unpacking Regional Variations in Biomanufacturing Excellence

In the Americas, established contract manufacturing hubs continue to benefit from a mature regulatory environment and deep technical expertise. North American sites are expanding capacity to meet the demands of high-value cell and gene therapy pipelines, while Latin American markets are gradually emerging through strategic partnerships and technology transfers that build local capabilities.

Across Europe, the Middle East and Africa, Western Europe remains a powerhouse region with cutting-edge facilities and strong government incentives. Meanwhile, Eastern European countries are attracting investment in cost-effective single-use and stainless steel infrastructure. Collaborations in the Middle East and Africa prioritize capacity building for vaccine production, reflecting broader public health objectives.

In Asia-Pacific, rapid growth is driven by sizeable domestic populations and supportive governmental frameworks. Facilities in China, South Korea and Southeast Asia are scaling swiftly, combining competitive cost structures with robust technical platforms. Providers in the region are increasingly serving global clients, underscoring Asia-Pacific’s rise as a strategic manufacturing pillar.

Profiling Strategic Leaders Steering the Contract Manufacturing Arena

A review of industry leaders reveals a landscape characterized by strategic investments in capacity expansion, technological differentiation and integrated service models. Leading companies have fortified their capabilities through acquisitions of specialized process technology developers and expansions of single-use production suites. Others have forged alliances with clinical research organizations to streamline the transition from development into commercial manufacturing.

Key players are deploying advanced automation and digital monitoring platforms to enhance process consistency and facilitate real-time release testing. Some have pioneered modular facility designs that support rapid project ramp-up, while others leverage vast global networks to offer sponsors multi-regional supply continuity. Collaboration agreements between contract manufacturers and academic research centers are also on the rise, fostering innovation in next-generation therapies.

Moreover, an emphasis on sustainability has prompted prominent providers to invest in energy-efficient bioreactors and circular consumption models for consumables, positioning environmental responsibility as a differentiator in provider selection.

Driving Competitive Advantage Through Targeted Strategic Initiatives

Industry participants should prioritize investments in digital transformation, deploying predictive analytics and process modeling to accelerate development timelines and reduce operational risk. By integrating end-to-end data streams, organizations can optimize process parameters, anticipate maintenance needs and enhance regulatory compliance.

Diversifying manufacturing footprints across geographies can mitigate trade-related uncertainties while ensuring continuity for clinical and commercial supply. Establishing flexible networks that encompass both single-use and stainless steel platforms allows for rapid scaling of production volumes and faster response to shifting demand profiles.

Cultivating collaborative partnerships with upstream technology innovators, academic institutions and regulatory agencies will facilitate seamless knowledge transfer and expedite regulatory approvals. At the same time, embedding sustainability strategies-such as water-saving systems and recyclable consumables-will address growing environmental considerations and strengthen corporate responsibility credentials.

Finally, embracing modular facility designs and virtual manufacturing partnerships can reduce capital burden, enabling smaller sponsors to access best-in-class production capabilities without prohibitive upfront investments.

Robust Research Framework Underpinning Trusted Market Insights

The research methodology underpinning this analysis combined extensive secondary research with qualitative interviews of senior executives, technical experts and regulatory stakeholders. Publicly available sources were scrutinized, including regulatory filings, corporate disclosures and patent databases, to map technological advances and capacity expansions.

Primary data was gathered through in-depth discussions with process engineers, quality assurance leaders and supply chain managers, providing firsthand insights into operational challenges and emerging best practices. This information was triangulated against quantitative indicators such as facility build-outs and technology adoption rates to ensure robustness.

Analytical rigor was maintained through iterative validation cycles, cross-referencing findings with external analysts and synthesizing divergent viewpoints into a cohesive narrative. The result is a research framework that delivers balanced perspectives, rooted in both empirical evidence and expert judgment, to inform strategic decision-making.

Concluding Strategic Imperatives for Biologics Manufacturing Success

The convergence of advanced biotherapeutic modalities, evolving regulatory expectations and shifting global trade dynamics underscores the critical importance of strategic foresight in biologics contract manufacturing. Organizations that align technological investments with flexible operational models and resilient supply networks will be best positioned to meet the demands of complex pipelines.

By integrating digital capabilities, diversifying geographic footprints and fostering collaborative innovation, industry leaders can drive efficiencies while maintaining the agility required for personalized medicine. Importantly, a proactive approach to sustainability and quality will not only address stakeholder expectations but also create long-term competitive differentiation.

As the sector continues to evolve, stakeholders equipped with deep segmentation insights, regional context and actionable recommendations will be empowered to capitalize on emerging opportunities and navigate uncertainties with confidence.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Molecule Type
    • Cell Therapy
    • Gene Therapy
    • Monoclonal Antibody
    • Recombinant Protein
    • Vaccine
  • Process Step
    • Analytical Testing
    • Downstream
    • Fill Finish
    • Formulation
    • Upstream
  • Production Scale
    • Commercial
    • Phase I
    • Phase II
    • Phase III
    • Preclinical
  • Technology Platform
    • Single Use System
    • Stainless Steel System
  • Therapeutic Area
    • Autoimmune
    • Infectious Disease
    • Oncology
    • Rare Disease
  • End User
    • Biotechnology Company
    • Contract Service Provider
    • Pharmaceutical Company
    • Research Institute
  • Manufacturing Model
    • Dedicated Facility
    • Fee For Service
    • Multiproduct Facility
    • Virtual Manufacturing
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Lonza Group Ltd.
  • Samsung Biologics Co., Ltd.
  • Catalent, Inc.
  • Wuxi Biologics (Cayman) Inc.
  • Thermo Fisher Scientific Inc.
  • Boehringer Ingelheim International GmbH
  • Fujifilm Diosynth Biotechnologies U.S.A., Inc.
  • AGC Biologics Inc.
  • Recipharm AB
  • KBI Biopharma, Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Biologics Contract Manufacturing Market, by Molecule Type
8.1. Introduction
8.2. Cell Therapy
8.3. Gene Therapy
8.4. Monoclonal Antibody
8.5. Recombinant Protein
8.6. Vaccine
9. Biologics Contract Manufacturing Market, by Process Step
9.1. Introduction
9.2. Analytical Testing
9.3. Downstream
9.4. Fill Finish
9.5. Formulation
9.6. Upstream
10. Biologics Contract Manufacturing Market, by Production Scale
10.1. Introduction
10.2. Commercial
10.3. Phase I
10.4. Phase II
10.5. Phase III
10.6. Preclinical
11. Biologics Contract Manufacturing Market, by Technology Platform
11.1. Introduction
11.2. Single Use System
11.3. Stainless Steel System
12. Biologics Contract Manufacturing Market, by Therapeutic Area
12.1. Introduction
12.2. Autoimmune
12.3. Infectious Disease
12.4. Oncology
12.5. Rare Disease
13. Biologics Contract Manufacturing Market, by End User
13.1. Introduction
13.2. Biotechnology Company
13.3. Contract Service Provider
13.4. Pharmaceutical Company
13.5. Research Institute
14. Biologics Contract Manufacturing Market, by Manufacturing Model
14.1. Introduction
14.2. Dedicated Facility
14.3. Fee For Service
14.4. Multiproduct Facility
14.5. Virtual Manufacturing
15. Americas Biologics Contract Manufacturing Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Biologics Contract Manufacturing Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Biologics Contract Manufacturing Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Lonza Group Ltd.
18.3.2. Samsung Biologics Co., Ltd.
18.3.3. Catalent, Inc.
18.3.4. Wuxi Biologics (Cayman) Inc.
18.3.5. Thermo Fisher Scientific Inc.
18.3.6. Boehringer Ingelheim International GmbH
18.3.7. Fujifilm Diosynth Biotechnologies U.S.A., Inc.
18.3.8. AGC Biologics Inc.
18.3.9. Recipharm AB
18.3.10. KBI Biopharma, Inc.
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. BIOLOGICS CONTRACT MANUFACTURING MARKET MULTI-CURRENCY
FIGURE 2. BIOLOGICS CONTRACT MANUFACTURING MARKET MULTI-LANGUAGE
FIGURE 3. BIOLOGICS CONTRACT MANUFACTURING MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 18. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2024 VS 2030 (%)
FIGURE 20. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. BIOLOGICS CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. BIOLOGICS CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BIOLOGICS CONTRACT MANUFACTURING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FILL FINISH, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SINGLE USE SYSTEM, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY STAINLESS STEEL SYSTEM, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY AUTOIMMUNE, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RARE DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANY, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY CONTRACT SERVICE PROVIDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANY, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY DEDICATED FACILITY, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY FEE FOR SERVICE, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MULTIPRODUCT FACILITY, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY VIRTUAL MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 58. CANADA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 59. CANADA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2030 (USD MILLION)
TABLE 60. CANADA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 61. CANADA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 62. CANADA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 63. CANADA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 64. CANADA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2030 (USD MILLION)
TABLE 65. MEXICO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 66. MEXICO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2030 (USD MILLION)
TABLE 67. MEXICO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 68. MEXICO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 69. MEXICO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 70. MEXICO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 71. MEXICO BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2030 (USD MILLION)
TABLE 86. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2030 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2030 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 94. UNITED KINGDOM BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 95. UNITED KINGDOM BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2030 (USD MILLION)
TABLE 96. UNITED KINGDOM BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 97. UNITED KINGDOM BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 98. UNITED KINGDOM BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 99. UNITED KINGDOM BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. UNITED KINGDOM BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2030 (USD MILLION)
TABLE 101. GERMANY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 102. GERMANY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2030 (USD MILLION)
TABLE 103. GERMANY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 104. GERMANY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 105. GERMANY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 106. GERMANY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 107. GERMANY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2030 (USD MILLION)
TABLE 108. FRANCE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 109. FRANCE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2030 (USD MILLION)
TABLE 110. FRANCE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 111. FRANCE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 112. FRANCE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 113. FRANCE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 114. FRANCE BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2030 (USD MILLION)
TABLE 115. RUSSIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 116. RUSSIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2030 (USD MILLION)
TABLE 117. RUSSIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 118. RUSSIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 119. RUSSIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 120. RUSSIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 121. RUSSIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2030 (USD MILLION)
TABLE 122. ITALY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 123. ITALY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2030 (USD MILLION)
TABLE 124. ITALY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 125. ITALY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 126. ITALY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 127. ITALY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 128. ITALY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2030 (USD MILLION)
TABLE 129. SPAIN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 130. SPAIN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2030 (USD MILLION)
TABLE 131. SPAIN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 132. SPAIN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 133. SPAIN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 134. SPAIN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 135. SPAIN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2030 (USD MILLION)
TABLE 136. UNITED ARAB EMIRATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 137. UNITED ARAB EMIRATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2030 (USD MILLION)
TABLE 138. UNITED ARAB EMIRATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 139. UNITED ARAB EMIRATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 140. UNITED ARAB EMIRATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 141. UNITED ARAB EMIRATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 142. UNITED ARAB EMIRATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2030 (USD MILLION)
TABLE 143. SAUDI ARABIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 144. SAUDI ARABIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2030 (USD MILLION)
TABLE 145. SAUDI ARABIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 146. SAUDI ARABIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 147. SAUDI ARABIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 148. SAUDI ARABIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 149. SAUDI ARABIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2030 (USD MILLION)
TABLE 150. SOUTH AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 151. SOUTH AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2030 (USD MILLION)
TABLE 152. SOUTH AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 153. SOUTH AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 154. SOUTH AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 155. SOUTH AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 156. SOUTH AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2030 (USD MILLION)
TABLE 157. DENMARK BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 158. DENMARK BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2030 (USD MILLION)
TABLE 159. DENMARK BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 160. DENMARK BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 161. DENMARK BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 162. DENMARK BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 163. DENMARK BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2030 (USD MILLION)
TABLE 164. NETHERLANDS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 165. NETHERLANDS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2030 (USD MILLION)
TABLE 166. NETHERLANDS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 167. NETHERLANDS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 168. NETHERLANDS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 169. NETHERLANDS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 170. NETHERLANDS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2030 (USD MILLION)
TABLE 171. QATAR BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 172. QATAR BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2030 (USD MILLION)
TABLE 173. QATAR BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 174. QATAR BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 175. QATAR BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 176. QATAR BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 177. QATAR BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2030 (USD MILLION)
TABLE 178. FINLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 179. FINLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2030 (USD MILLION)
TABLE 180. FINLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 181. FINLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 182. FINLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 183. FINLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 184. FINLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2030 (USD MILLION)
TABLE 185. SWEDEN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 186. SWEDEN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2030 (USD MILLION)
TABLE 187. SWEDEN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 188. SWEDEN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 189. SWEDEN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 190. SWEDEN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 191. SWEDEN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2030 (USD MILLION)
TABLE 192. NIGERIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 193. NIGERIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2030 (USD MILLION)
TABLE 194. NIGERIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 195. NIGERIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 196. NIGERIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 197. NIGERIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 198. NIGERIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2030 (USD MILLION)
TABLE 199. EGYPT BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 200. EGYPT BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2030 (USD MILLION)
TABLE 201. EGYPT BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 202. EGYPT BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 203. EGYPT BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 204. EGYPT BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 205. EGYPT BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2030 (USD MILLION)
TABLE 206. TURKEY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 207. TURKEY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2030 (USD MILLION)
TABLE 208. TURKEY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 209. TURKEY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 210. TURKEY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 211. TURKEY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 212. TURKEY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2030 (USD MILLION)
TABLE 213. ISRAEL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 214. ISRAEL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2030 (USD MILLION)
TABLE 215. ISRAEL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 216. ISRAEL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 217. ISRAEL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 218. ISRAEL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 219. ISRAEL BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2030 (USD MILLION)
TABLE 220. NORWAY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 221. NORWAY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2030 (USD MILLION)
TABLE 222. NORWAY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 223. NORWAY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 224. NORWAY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 225. NORWAY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 226. NORWAY BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2030 (USD MILLION)
TABLE 227. POLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 228. POLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2030 (USD MILLION)
TABLE 229. POLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 230. POLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 231. POLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 232. POLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 233. POLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2030 (USD MILLION)
TABLE 234. SWITZERLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 235. SWITZERLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2030 (USD MILLION)
TABLE 236. SWITZERLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 237. SWITZERLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 238. SWITZERLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 239. SWITZERLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 240. SWITZERLAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2030 (USD MILLION)
TABLE 241. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 242. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2030 (USD MILLION)
TABLE 243. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 244. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 245. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 246. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 247. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2030 (USD MILLION)
TABLE 248. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 249. CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 250. CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2030 (USD MILLION)
TABLE 251. CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 252. CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 253. CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 254. CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 255. CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2030 (USD MILLION)
TABLE 256. INDIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 257. INDIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2030 (USD MILLION)
TABLE 258. INDIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 259. INDIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 260. INDIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 261. INDIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 262. INDIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2030 (USD MILLION)
TABLE 263. JAPAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 264. JAPAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2030 (USD MILLION)
TABLE 265. JAPAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 266. JAPAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 267. JAPAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 268. JAPAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 269. JAPAN BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2030 (USD MILLION)
TABLE 270. AUSTRALIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 271. AUSTRALIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2030 (USD MILLION)
TABLE 272. AUSTRALIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 273. AUSTRALIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 274. AUSTRALIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 275. AUSTRALIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 276. AUSTRALIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2030 (USD MILLION)
TABLE 277. SOUTH KOREA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 278. SOUTH KOREA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2030 (USD MILLION)
TABLE 279. SOUTH KOREA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 280. SOUTH KOREA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 281. SOUTH KOREA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 282. SOUTH KOREA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 283. SOUTH KOREA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2030 (USD MILLION)
TABLE 284. INDONESIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 285. INDONESIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2030 (USD MILLION)
TABLE 286. INDONESIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 287. INDONESIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 288. INDONESIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 289. INDONESIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 290. INDONESIA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2030 (USD MILLION)
TABLE 291. THAILAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 292. THAILAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS STEP, 2018-2030 (USD MILLION)
TABLE 293. THAILAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCTION SCALE, 2018-2030 (USD MILLION)
TABLE 294. THAILAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2030 (USD MILLION)
TABLE 295. THAILAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 296. THAILAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 297. THAILAND BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY MANUFACTURING MODEL, 2018-2030 (USD MILLION)
TABLE 298. PHILIPPINES BIOL

Companies Mentioned

The companies profiled in this Biologics Contract Manufacturing market report include:
  • Lonza Group Ltd.
  • Samsung Biologics Co., Ltd.
  • Catalent, Inc.
  • Wuxi Biologics (Cayman) Inc.
  • Thermo Fisher Scientific Inc.
  • Boehringer Ingelheim International GmbH
  • Fujifilm Diosynth Biotechnologies U.S.A., Inc.
  • AGC Biologics Inc.
  • Recipharm AB
  • KBI Biopharma, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages181
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 31.04 Billion
Forecasted Market Value ( USD ) by 2030 $ 67.56 Billion
Compound Annual Growth Rate16.8%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Biologics Contract Development & Manufacturing Organization Market by Service Type, Expression System, Therapeutic Category, Development Phase, End User - Global Forecast to 2030 - Product Image

Biologics Contract Development & Manufacturing Organization Market by Service Type, Expression System, Therapeutic Category, Development Phase, End User - Global Forecast to 2030

  • Report
  • 192 Pages
  • Global
From
Biologics Contract Development Market by Service Type, Molecule Type, Therapeutic Area, Host System, End User, Technology - Global Forecast to 2030 - Product Image

Biologics Contract Development Market by Service Type, Molecule Type, Therapeutic Area, Host System, End User, Technology - Global Forecast to 2030

  • Report
  • 186 Pages
  • Global
From
Biopharmaceuticals Contract Manufacturing Market Size, Share, & Trend Analysis Report by Source, Service (Process Development), Drug Type (Biologics, Biosimilars), Type, Scale of Operation, Therapeutic Area, Region, and Segment Forecasts, 2025-2030 - Product Image

Biopharmaceuticals Contract Manufacturing Market Size, Share, & Trend Analysis Report by Source, Service (Process Development), Drug Type (Biologics, Biosimilars), Type, Scale of Operation, Therapeutic Area, Region, and Segment Forecasts, 2025-2030

  • Report
  • 150 Pages
  • Global
From
Biologics Contract Manufacturing Market Size, Share & Trends Analysis Report By Product, By Indication, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Biologics Contract Manufacturing Market Size, Share & Trends Analysis Report By Product, By Indication, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 180 Pages
  • Global
From
Biologics Fill Finish Services Market: Industry Trends and Global Forecasts to 2035 - Product Image

Biologics Fill Finish Services Market: Industry Trends and Global Forecasts to 2035

  • Report
  • 470 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.